Literature DB >> 2970263

Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.

P N Sambrook1, J A Eisman, G D Champion, N A Pocock.   

Abstract

Sex hormones have important effects on bone, especially in postmenopausal women. These hormones may be of particular significance in patients with rheumatoid arthritis (RA), who have a high frequency of osteoporosis. To examine this, we measured estrogen and androgen concentrations and bone mineral density (BMD) in 49 postmenopausal women with RA and 49 normal postmenopausal women. Compared with the controls, postmenopausal RA patients had significantly reduced levels of estrone (median 18 pmoles/liter versus 49; P less than 0.001), dehydroepiandosterone sulfate (DHEAS) (median 0.3 mumoles/liter versus 2.0; P less than 0.001), testosterone (median 0.6 nmoles/liter versus 0.95; P less than 0.001), and femoral BMD (mean 0.72 gm/cm2 versus 0.80; P less than 0.002). Prednisolone therapy in 22 patients (mean dosage 8 mg/day) was associated with reductions in estrone and testosterone levels; however, DHEAS and femoral BMD were also decreased in RA patients who were not receiving corticosteroids. Reduced DHEAS levels in postmenopausal women with RA may increase their risk of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970263     DOI: 10.1002/art.1780310805

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  25 in total

Review 1.  The role of prolactin in the pathogenesis of autoimmune disease.

Authors:  Istvan Berczi
Journal:  Endocr Pathol       Date:  1993-12       Impact factor: 3.943

2.  A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity.

Authors:  L Mirone; L Altomonte; P D'Agostino; A Zoli; A Barini; M Magaro
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

3.  Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis.

Authors:  H R van den Brink; W F Lems; A A van Everdingen; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1993-04       Impact factor: 19.103

4.  Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  R H Straub; C Weidler; B Demmel; M Herrmann; F Kees; M Schmidt; J Schölmerich; J Schedel
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

5.  Rheumatoid arthritis, the contraceptive pill, and androgens.

Authors:  W H James
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

6.  Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  P Härle; G Pongratz; C Weidler; R Büttner; J Schölmerich; R H Straub
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

7.  Effect of 1 alpha-vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment.

Authors:  J Aerssens; R Van Audekercke; M Talalaj; P Van Vlasselaer; E Bramm; P Geusens; J Dequeker
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

8.  Association of serum dehydroepiandrosterone sulfate and cognition in older adults: sex steroid, inflammatory, and metabolic mechanisms.

Authors:  Kerry L Hildreth; Wendolyn S Gozansky; Catherine M Jankowski; Jim Grigsby; Pamela Wolfe; Wendy M Kohrt
Journal:  Neuropsychology       Date:  2013-05       Impact factor: 3.295

9.  Biomarks in secondary osteoporosis.

Authors:  A Aroso Dias; A Lopes Vaz; M Hargreaves; C Afonso; D Araújø; T Bravo
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

10.  A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Lori B Chibnik; Monica McGrath; Shun-Chiao Chang; Brendan T Keenan; Karen H Costenbader; Patricia A Fraser; Shelley Tworoger; Susan E Hankinson; I-Min Lee; Julie Buring; Immaculata De Vivo
Journal:  Arthritis Res Ther       Date:  2009-06-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.